CRISPR/CasX based gene therapy (Biogen/Scribe Therapeutics)

N/A

Report date: 2025/08/15 17:43:00

Base Information

Drug NameCRISPR/CasX based gene therapy (Biogen/Scribe Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesScribe Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesScribe Therapeutics IncBiogen Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A